Skin Cancer Diagnostics Market Scope And Analysis

  • Report Code : TIPRE00018116
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 197
Buy Now

Global Skin Cancer Diagnostics Market Analysis Report 2022 to 2028

Buy Now

Global Skin Cancer Diagnostics Market Report Global Skin Cancer Diagnostics Market Size and Share Global Skin Cancer Diagnostics Market Scope and Analysis

Global Skin Cancer Diagnostics Market Report Scope

Report Attribute Details
Market size in 2021 US$ 3.36 Billion
Market Size by 2028 US$ 5.48 Billion
Global CAGR (2021 - 2028) 7.2%
Historical Data 2019-2020
Forecast period 2022-2028
Segments Covered By Type
  • Melanoma and Non-Melanoma
By Screening Type
  • Blood Tests
  • Dermatoscopy
  • Imaging Tests
  • Lymph Node Biopsy
  • Skin Biopsy
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • SkylineDx BV
  • AMLo Biosciences Limited
  • NeraCare GmbH
  • DermLite LLC
  • bioMerieux SA
  • Veriskin Inc
  • Castle Biosciences Inc
  • DermTech Inc
  • HOFFMANN LA ROCHE LTD

    • Key Market Players:

    • SkylineDx BV (Netherlands)
    • AMLo Biosciences Limited (UK)
    • NeraCare GmbH (Germany)
    • DermLite LLC (USA)
    • bioMerieux SA (France)
    • Veriskin Inc (US)
    • Castle Biosciences, Inc. (US)
    • DermTech Inc (US)
    • HOFFMANN-LA ROCHE LTD (Switzerland)
    • Michelson Diagnostics Ltd (UK)

    Key Developments:

    • December 2021:

      SkyineDx entered into a 3-year strategic partnership with Life Sciences’ institute VIB for the evaluation and initiation of collaborative projects focused on molecular diagnostics.

    • July 2020:

      Veriskin received US FDA breakthrough device designation for its TruScore device.

    • April 2021:

      Castle Biosciences, Inc. signed a definitive agreement to acquire entire equity of Myriad myPath, LLC (Myriad myPath Laboratory) from Myriad Genetics for US$ 32.5 million.

    Report Coverage

    The global skin cancer diagnostics market research report provides detailed insights into the market in terms of size, share, trends, and forecasts. It delivers crisp and precise know-how of drivers, restraints, opportunities, segments, and industrial landscape. The COVID-19 impact analysis is discussed with the consequences followed in global and regional markets. A list of key market players with their respective developments in recent years has been reserved as a special mention.